Company intelligence / Profile preview

HDX

Luxembourg City, Luxembourg

Ownership: Private
Development stage: Other

Overview

HDX Pharma is a biotechnology company dedicated to developing first-in-class small molecule therapeutics for the treatment of Huntington's disease. The company's lead program focuses on modulating the huntingtin protein to address the underlying genetic cause of the neurodegenerative disorder. By targeting the specific molecular mechanisms of protein aggregation and toxicity, HDX Pharma aims to provide disease-modifying options for patients. The company was founded based on research from the University of Auckland and the Max Planck Institute, leveraging deep expertise in medicinal chemistry and neurobiology.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

University of AucklandMax Planck Institute

Beyond the preview

Go deeper on HDX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HDX.

Explore the full profile